Avita Medical(NASDAQ) RCEL

AVITA Medical helps people with burns or skin conditions heal using their own skin cells. Its main product, RECELL, lets doctors treat wounds with a spray made from a small skin sample. This technology helps patients recover faster and with less pain.

Skin in the Game: Products and Services

• RECELL System: Device for creating spray-on skin cells from a patient’s own skin; 98% of commercial revenue in 2024; used for burns and skin defects.
• PermeaDerm: Biosynthetic wound covering for burns and chronic wounds; approximately 2% of commercial revenue in 2024; distributed in the U.S.
• Cohealyx: Collagen-based wound matrix for skin repair; FDA-cleared in December 2024; U.S. distribution agreement in place.
• RECELL GO and GO mini: Newer, easier-to-use versions of RECELL; FDA-approved in 2024; designed for hospital and clinic use.
• Lease Revenue: Income from leasing RECELL devices; less than 1% of commercial revenue in 2024.

Growth Spurts: Expansion and Partnerships

• Launched RECELL GO in 2024 after FDA approval; FDA approved RECELL GO mini in December 2024, with launch scheduled for the first quarter of 2025.
• Signed exclusive U.S. distribution deals for PermeaDerm and Cohealyx in 2024.
• Expanded into 16 countries with new distribution agreements by 2024.
• Formed research partnerships with University of Colorado School of Medicine and Houston Methodist Research Institute.
• Upgraded Ventura, California, production facility in 2024 to boost manufacturing.

What Makes AVITA Medical Stand Out

AVITA Medical’s patented RECELL technology is FDA-approved and used in major U.S. burn centers. The company’s global distribution network covers the U.S. Europe, Japan, Australia, and the UK. Strong intellectual property and exclusive partnerships support its position in regenerative wound care.

Five Things You Need to Know

• Revenue was $64.3 million in FY 2024, up 28% from FY 2023.
• RECELL products made up 98% of commercial sales in FY 2024.
• Gross profit margin was 85.8% in FY 2024, up from 84.5% in FY 2023.
• Net loss was $61.8 million in FY 2024, up from $35.4 million in FY 2023.

Bottom Line

AVITA Medical has grown by expanding its product line and global reach. The company focuses on innovation in wound care, but continues to face operating losses as it invests in growth.